
Mesa Laboratories, Inc.
NASDAQ•MLAB
CEO: Mr. Gary M. Owens
セクター: Technology
業種: Hardware, Equipment & Parts
上場日: 1984-02-29
Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides testing and laboratory services to the dental and pharmaceutical industries. The Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for inherited genetic disease testing, pharmacogenetics, oncology testing, infectious disease testing, doping and toxicology testing, and other differentiated applications for use in research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; PurePep Chorus and Symphony instruments for peptide synthesis; and PurePep EasyClean products for purifying peptides. The Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as environmental and process monitoring, dialysis, gas flow, air quality, and torque testing in medical device and pharmaceutical manufacturing, laboratory, and hospital environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems, offered under DialyGuard, ViewPoint, DataTrace, DryCal, and BGI brands. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.
連絡先情報
時価総額
$489.66M
PER (TTM)
131.3
28.2
配当利回り
0.7%
52週高値
$152.03
52週安値
$55.45
52週レンジ
順位32Top 23.6%
4.9
F-Score
改良版 Piotroski 分析
10年ファンダメンタル
堅調 • 4.9 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2016-2025
財務ダッシュボード
Q3 2026 データ
売上高
$65.13M+3.64%
直近4四半期の推移
EPS
$0.66-312.90%
直近4四半期の推移
フリーCF
$18.02M+2.25%
直近4四半期の推移
2026 Q3 決算ハイライト
主なハイライト
Quarterly Net Income Soars Quarterly net income reached $3.63M, showing 316.6% increase compared to prior period loss of $1.68M.
Nine Month Revenue Growth Nine month revenues totaled $185.41M, marking 3.7% growth, while Net Income grew 111.1% to $10.85M.
Working Capital Turns Positive Working capital improved to $51.2M from negative $(61.3)M after settling $97.5M convertible notes debt during nine months.
Basic Earnings Per Share Doubles Basic EPS for nine months was $1.97, significantly higher than $0.95 reported in the comparable prior period.
リスク要因
China Market Uncertainty Persists Clinical Genomics revenue declined 6.7% for nine months due to China macroeconomic uncertainty and heightened trade tensions.
Genomics Unit Impairment Risk Clinical Genomics unit remains sensitive to impairment; fair value exceeded carrying value by 40% in recent annual test.
Currency and Tariff Margin Pressure Weak USD and tariffs reduced consolidated gross profit margin by 0.8 points for nine months, impacting several divisions.
G&A Expense Rises General and administrative expense rose 3.4% for nine months, driven by higher allowance for uncollectible China receivables.
見通し
Credit Facility Spread Reduced Amended Credit Facility reduced interest spread, expected to save approximately $0.4M annually on current debt balances.
Focus on Core Growth Future growth relies on expanding customer base and integrating acquisitions, focusing on Biopharma and Sterilization segments.
New Tax Legislation Incorporated Incorporated provisions of OBBBA into tax provision, resulting in reduction of U.S. current tax expense for fiscal year 2026.
Continued Dividend Payments Company continues regular quarterly dividend payments of $0.16 per share, maintaining commitment to shareholder returns.
同業比較
売上高 (TTM)
XRX$7.02B
$3.04B
$412.00M
粗利益率 (最新四半期)
EGAN73.1%
SATL67.8%
MLAB64.2%
主要指標
銘柄コード | 時価総額 | PER (TTM) | ROE (TTM) | 負債比率 |
|---|---|---|---|---|
| VPG | $603.00M | 113.9 | 1.6% | 14.0% |
| MLAB | $489.66M | 131.3 | 2.1% | 23.8% |
| LPTH | $487.74M | -0.1 | -48.3% | 6.8% |
長期トレンド
直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
1.6%
緩やかな成長
4四半期純利益CAGR
N/M
収益構造の変化
キャッシュフロー安定性
100%
優れたキャッシュフローの実績
深度リサーチ
次回決算:2026年5月26日
EPS:-
|売上高:-
財務レポート
財務データ
ニュース
全年度
Form 10-Q - Q3 2026
会計期末: 2025年12月31日|提出日: 2026年2月3日|売上高: $65.13M+3.6%|EPS: $0.66-312.9%予想を下回るForm 10-Q - Q2 2026
会計期末: 2025年9月30日|提出日: 2025年11月6日|売上高: $60.74M+5.0%|EPS: $0.45-28.6%予想を下回るForm 10-Q - Q1 2026
会計期末: 2025年6月30日|提出日: 2025年8月5日|売上高: $59.54M+2.4%|EPS: $0.87+38.1%予想を下回るForm 10-K - FY 2025
会計期末: 2025年3月31日|提出日: 2025年5月28日|売上高: $240.98M+11.5%|EPS: $-0.36+99.2%予想を下回るForm 10-Q - Q3 2025
会計期末: 2024年12月31日|提出日: 2025年2月4日|売上高: $62.84M+17.5%|EPS: $-0.31-179.5%予想を下回るForm 10-Q - Q2 2025
会計期末: 2024年9月30日|提出日: 2024年11月7日|売上高: $57.83M+8.8%|EPS: $0.63-373.9%予想を下回るForm 10-Q - Q1 2025
会計期末: 2024年6月30日|提出日: 2024年8月5日|売上高: $58.17M+14.9%|EPS: $0.63-730.0%予想を下回るForm 10-K - FY 2024
会計期末: 2024年3月31日|提出日: 2024年6月28日|売上高: $216.19M-1.3%|EPS: $-47.20-27864.7%予想を下回る